Clinical Trial Update: Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial update examining the kinetics, efficacy, and safety of IVIG-L in patients with hypogammaglobulinemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogammaglobulinemia

Drugs mentioned

• IVIG-L

Snippet

Sponsor: Prothya Biosolutions | Conditions: Hypogammaglobulinemia | Phase 2, Phase 3 | Status: COMPLETED